Uterine fibroids are among the most commonly found incidental findings in women undergoing fertility investigations. A pelvic ultrasound performed as part of a routine fertility work-up reports one or more fibroids — and immediately, before any clinical context has been provided, the couple begins to worry. Are the fibroids causing the infertility? Do they need to be removed before IVF can proceed? Will surgery make things better or worse?
These are entirely reasonable questions. And the answers — which are more nuanced and more individualized than a simple yes or no can convey — deserve the thorough explanation this article provides.
The short answer to the question in this article's title is: not always. Whether a fibroid needs to be removed before IVF depends entirely on its location, its size, its relationship to the uterine cavity, and the specific clinical picture of the individual patient. Some fibroids need to be treated before IVF and some do not. Some fibroids require surgical removal and others can be managed conservatively. And the decision — which requires clinical judgment informed by the complete assessment of both partners — is one of the most nuanced in fertility medicine.
What Are Uterine Fibroids?
Uterine fibroids — also called leiomyomas or myomas — are benign (non-cancerous) tumors that develop from the smooth muscle cells of the uterine wall. They are the most common benign tumors in women of reproductive age, affecting approximately 20 to 40 percent of women over the age of 35. They vary enormously in size — from a few millimeters to several centimetres — and in number — from a single fibroid to dozens distributed throughout the uterus.
Fibroids are classified by their location within the uterine wall, and this classification is the single most important determinant of their clinical significance for fertility.
Submucosal fibroids grow into the uterine cavity — projecting from the inner surface of the uterine wall into the space where the embryo must implant. They are the smallest proportion of all fibroids by frequency but the most clinically significant for fertility. Even small submucosal fibroids — as small as 1 to 2 cm — can significantly impair implantation by distorting the endometrial surface, disrupting the blood supply to the overlying endometrium, and creating an inflammatory endometrial environment hostile to implantation.
Intramural fibroids grow within the uterine muscle wall — the myometrium — without projecting significantly into the cavity or onto the outer surface. They are the most common type of fibroid. Their clinical significance for fertility depends primarily on their size and on whether they distort the uterine cavity — large intramural fibroids can cause cavity distortion even without a submucosal component.
Subserosal fibroids grow outward from the outer surface of the uterus — projecting into the pelvic cavity rather than into the uterine cavity. They are the least likely of the three types to affect fertility directly, because their outward growth does not distort the cavity where implantation occurs. Very large subserosal fibroids can occasionally compress adjacent structures — the fallopian tubes, the ureters — but small and medium subserosal fibroids are generally of limited fertility significance.
How Fibroids Affect Fertility
The mechanism through which fibroids impair fertility is primarily through their effect on the uterine cavity — the environment in which implantation must occur.
Submucosal fibroids distort the endometrial surface directly. The fibroid tissue that projects into the cavity alters the geometry of the uterine interior, creates areas of abnormal endometrial blood supply, and produces a local inflammatory response that changes the endometrial environment in ways that reduce receptivity. The clinical evidence for the negative effect of submucosal fibroids on IVF outcomes is consistent and significant — multiple studies have demonstrated reduced implantation rates and live birth rates in IVF cycles in women with submucosal fibroids compared to women without them.
Intramural fibroids have a more complex and debated relationship with fertility. Large intramural fibroids — generally those above 4 to 5 cm — can cause endometrial cavity distortion even without a submucosal component, and this distortion carries similar fertility implications to submucosal fibroids. Small to medium intramural fibroids without cavity distortion are less clearly associated with impaired fertility, and the evidence for a benefit from removing them before IVF is less conclusive than for submucosal fibroids.
Subserosal fibroids do not directly distort the uterine cavity and have limited direct impact on IVF outcomes in most cases. Their removal is generally not indicated for fertility purposes unless they are causing significant anatomical distortion of adjacent structures.
Beyond cavity effects, fibroids can affect fertility through additional mechanisms. Very large fibroids can impair uterine blood flow. Multiple fibroids can significantly reduce the functional endometrial surface area. And fibroids in specific locations — particularly at or near the cornua, where the fallopian tubes enter the uterus — can obstruct the intramural portion of the tube and prevent sperm entry.
The Classification System That Guides Clinical Decision-Making
The most clinically useful classification system for fibroids in the fertility context is the FIGO (International Federation of Gynecology and Obstetrics) fibroid classification, which grades fibroids from type 0 (pedunculated submucosal, entirely within the cavity) to type 8 (parasitic, separate from the uterus). The types most relevant to fertility are types 0, 1, and 2 (submucosal — within or abutting the cavity), types 3 and 4 (intramural — within the wall, touching or not touching the endometrium), and types 5, 6, and 7 (subserosal — on or outside the outer surface).
This classification — which requires both ultrasound and, ideally, hysteroscopic or MRI assessment for complete characterization — provides the most precise description of each fibroid's location and its relationship to the cavity. The clinical management decision for each fibroid depends primarily on its FIGO classification.
The Critical Role of Hysteroscopy in Fibroid Assessment
Standard transvaginal ultrasound identifies most fibroids and provides information about their approximate location. But for the most clinically important question — does this fibroid distort or involve the uterine cavity, and if so, to what degree — ultrasound alone is frequently insufficient.
Hysteroscopy — the direct visualization of the uterine cavity through a thin camera passed through the cervix — provides the definitive assessment of cavity involvement. Under direct hysteroscopic vision, the surgeon can see precisely how much of a fibroid projects into the cavity, how it affects the endometrial surface, and what the cavity geometry looks like with the fibroid in situ.
This direct visualization has direct clinical implications. A fibroid that appears purely intramural on ultrasound may, on hysteroscopy, have a small submucosal component that distorts the cavity. A fibroid that appears borderline for submucosal involvement on ultrasound is definitively characterized as submucosal or intramural only by hysteroscopy. And the decision about surgical treatment — whether to remove the fibroid before IVF, and if so how — is most accurately made after hysteroscopic assessment rather than ultrasound alone.
At Metro IVF, hysteroscopy is part of the standard pre-IVF assessment for all women with identified fibroids, because the additional information it provides is essential for the surgical decision — and because it simultaneously identifies any other uterine cavity abnormalities that may be contributing to the clinical picture.
When Fibroids Should Be Removed Before IVF
The clinical guideline that is most consistently supported by the evidence is the following: fibroids that distort the uterine cavity should be removed before IVF because the evidence for impaired IVF outcomes with untreated cavity-distorting fibroids is consistent and the evidence for improvement after surgical removal is meaningful.
Submucosal fibroids (FIGO types 0, 1, and 2) — all fibroids with a significant intracavitary component — should generally be removed before IVF. The hysteroscopic myomectomy procedure — removal of the fibroid through the hysteroscope, without any external incision — is appropriate for fibroids that are predominantly within the cavity (FIGO types 0 and 1) and for fibroids with up to 50 percent intramural extension (FIGO type 2 if below 5 cm). The procedure is performed under general anaesthesia, requires no external incision, and carries a recovery time of one to three weeks before fertility treatment can be resumed.
Large intramural fibroids causing cavity distortion — typically those above 4 to 5 cm in diameter that are documented to distort the cavity on hysteroscopy or MRI — are also generally managed surgically before IVF, through open or laparoscopic myomectomy. The surgery is more involved than hysteroscopic myomectomy, requiring a recovery period of four to twelve weeks depending on the surgical approach, and carries specific risks including uterine scar formation that requires careful management in subsequent pregnancy.
Fibroids obstructing the cornua or the tubal ostia — regardless of size — impair sperm access to the tube and should be assessed carefully. If the obstruction is confirmed to be from the fibroid, treatment before IVF is appropriate.
When Fibroids Do Not Need to Be Removed Before IVF
The clinical situations in which fibroid removal before IVF is not indicated — where proceeding with IVF without surgery is the more appropriate recommendation — are equally important to understand.
Small intramural fibroids without cavity distortion. For intramural fibroids below 3 to 4 cm that do not distort the uterine cavity — confirmed by hysteroscopy — the evidence for IVF outcome impairment is limited, and the evidence that surgical removal improves IVF outcomes in this group is not consistent. For these fibroids, proceeding with IVF without surgery is generally appropriate. The fibroid is monitored during the stimulation cycle — very rarely, rapid fibroid growth during ovarian stimulation from the high estrogen environment can cause symptoms that require attention — but is not treated before the IVF cycle.
Subserosal fibroids of any size not distorting adjacent structures. Subserosal fibroids that are not causing tubal obstruction or other anatomical complications do not warrant pre-IVF surgical removal for fertility purposes. Their presence does not impair IVF outcomes, and the surgical risks of removing them — including adhesion formation that could impair fertility — exceed the clinical benefit.
Multiple small fibroids in a woman with diminished ovarian reserve. For women with very low ovarian reserve where the surgical recovery period represents a significant time cost in terms of biological aging, the decision to operate must explicitly weigh the potential benefit of removing non-cavity-distorting fibroids against the cost of the recovery time. In women with AMH below 0.5 ng/mL who are already working against the clock, delaying IVF for a myomectomy that removes fibroids that are not clearly impairing outcomes may do more harm than good.
Fibroids in a woman who has had previous successful implantation with the same fibroids present. If a previous IVF cycle — or a natural pregnancy — resulted in successful implantation with the fibroids in their current size and configuration, the fibroids are not the primary obstacle and removal before the next cycle is difficult to justify.
The Risks of Myomectomy That Must Be Considered
The decision to remove a fibroid before IVF is not cost-free. Myomectomy — whether hysteroscopic or open/laparoscopic — carries specific risks that must be weighed against the potential benefit for each individual patient.
Uterine scar formation. Open or laparoscopic myomectomy creates a scar in the uterine wall. This scar can be associated with intrauterine adhesions — particularly if the surgery involves entry into the uterine cavity. Adhesions reduce the functional endometrial surface area and can impair implantation — potentially creating a uterine cavity problem where only a fibroid problem existed before.
Ovarian reserve reduction. Surgical procedures near the ovaries — including laparoscopic surgery with the instruments working in the pelvic cavity — can occasionally compromise ovarian blood supply and reduce ovarian reserve. This risk is small but real, particularly in women with borderline reserve.
Recurrence. Fibroids grow from remaining smooth muscle cells, and new fibroids can develop in the uterus after myomectomy. Women who have a myomectomy and then delay IVF for an extended period may find that new fibroids have developed in the interim.
Surgical complications. As with any surgical procedure, myomectomy carries risks of bleeding, infection, and anaesthetic complications — all of which, while rare with skilled surgeons, are not zero.
These risks do not mean fibroid removal is the wrong recommendation when the clinical evidence supports it. They mean the recommendation must be based on a genuine benefit-risk assessment rather than a blanket policy of removing all fibroids before IVF.
The Metro IVF Decision Framework
At Metro IVF in Ambikapur, the decision about fibroids and IVF follows a consistent framework that applies the clinical evidence to the individual patient.
Every woman with identified fibroids undergoes hysteroscopic assessment before the decision about treatment is made — because the hysteroscopic finding is the most clinically meaningful determinant of the surgical decision.
If the hysteroscopy confirms cavity distortion — a submucosal fibroid or a large intramural fibroid with documented endometrial involvement — the clinical recommendation is generally surgical removal before IVF, with the specific surgical approach (hysteroscopic, laparoscopic, or open) determined by the fibroid's FIGO classification and size.
If the hysteroscopy confirms no cavity involvement — a purely intramural or subserosal fibroid with a normal cavity — the clinical recommendation is generally to proceed with IVF without surgery, with the fibroid monitored during the stimulation cycle.
In all cases, the recommendation is discussed with the couple — including the evidence for and against surgical intervention, the specific risks of the surgery, the recovery timeline and its implications for IVF timing, and the realistic expectation about what surgery is and is not likely to achieve for their specific clinical picture.
This is the clinical engagement that the fibroid-and-IVF question deserves — not a blanket policy, but an individualized decision grounded in the best available evidence and applied to the specific features of each patient's presentation.
Your Next Step
If you have been told that you have uterine fibroids and are considering IVF — or if you have been advised to have fibroid surgery before IVF and want to understand whether that recommendation is appropriate for your specific situation — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur provides the most thorough and honest clinical assessment available.
The decision about fibroids and IVF is one of the most nuanced in fertility medicine. It deserves a specialist's attention — not a policy.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Fibroids and IVF — the right decision depends on your specific fibroid, your specific cavity, and your specific clinical picture. Book your consultation with Dr. Soni at Metro IVF today.